Additionally, olaparib possesses approval for first-line maintenance therapy in BRCA variant ovarian cancer as well as approval for maintenance therapy of BRCA1/2 variant pancreatic cancer (Robson et al., 2017; Litton et al., 2018; FDA, 2020a; Madariaga et al., 2020). This evidence concerns the gene BRCA1 and ovarian cancer.